Clinical trial · Observational
Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
An Exploratory Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP) in Israel
NCT01202786CI-TRIAL-00007827completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is in cancer of unknown primary (CUP) patients, to compare the cost-effectiveness of miRview™ mets test with conventional work-up in identifying the primary tumor site.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms, Unknown Primary | Neoplasm | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- miRview mets Disclosed
- description
- Patients of group 1 will be submitted to the standard conventional work-up (see below) as well as miRview™ mets assay. Their physician will treat the patient based upon both results
- label
- Control
- description
- Patients of group 2 will be submitted to the standard conventional work-up. miRview™ mets assay will be performed but will remain blinded for both the patient and referring physician. Treatment will be decided based on standard work-up results
Primary outcomes (1)
- measure
- cost-effectiveness
- timeFrame
- 18 months
- description
- To compare the cost-effectiveness of miRview™ mets test with conventional work-up in cancer of unknown primary (CUP) patients, by comparing total cost and time of the diagnostic process (including hospitalization time) from day 1 of the study to the decision on treatment program
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who present with histologically-confirmed metastatic cancer in whom an initial work-up which consists of detailed medical history, physical examination, basic laboratory studies, histopathological review of biopsy material, and CT scan of the chest abdomen and pelvis fail to identify the primary site. 2. Older than 18 years 3. Performance status \<2 4. life expectancy \>3 months 5. ANC \>1500 6. Platelets \>100,000 if bone marrow is not involved 7. Hb \> 9 8. Creatinine \<2 9. LFTS \< x5 normal 10. Histology proven of malignancy 11. Enough material for miRview test (10 slices of 10 micrometer sections) 12. Member of Clalit HMO Exclusion Criteria: 1. Patients unable or unwilling to sign the informed consent form 2. Under 18 years old 3. Performance status \>2 4. life expectancy\<3 months 5. ANC \<1500 6. Platelets \<100,000 if marrow not involved 7. Hb \< 9 8. Creatinine \>2 9. LFTS \> x5 normal 10. Not member of Clalit HMO
References
Publications (0)
Data not yet available
No reference posted for this study.